Search

Your search keyword '"Albanesi, Marcello"' showing total 159 results
Start Over Author "Albanesi, Marcello"
159 results on '"Albanesi, Marcello"'

2. Cannabidiol modulation of immune cell function: in vitro insights and therapeutic implications for atopic dermatitis.

Author

Chaoul, Nada, Palazzo, Stefano, Cinquantasei, Alessandro, Aresta, Vincenzo, De Chirico, Concetta, and Albanesi, Marcello

Subjects
B cells, ATOPIC dermatitis, CYTOTOXINS, T cells, CELL physiology
Abstract

Introduction: Cannabidiol (CBD) exhibits neuroprotective, anti-inflammatory, and immunomodulatory properties, making it a promising candidate for addressing inflammatory skin disorders like atopic dermatitis. Aim: This study aimed to (i) investigate CBD's impact on lymphocyte proliferation and lymphocyte viability; (ii) assess in vitro cytotoxicity U937 cells (a human promonocytic cell line) of CBD/cytotoxicity of CBD on U937 cells; (iii) provide insights into CBD immunomodulatory potential, and (iv) evaluate suitability of CBD for treating inflammatory skin conditions. Material and methods: To this aim PBMCs from healthy donors were cultured with mitogen and two different CBD doses (0.1 and 1 mg/ml), assessing B and T cell proliferation through flow cytometry. CBD inhibited mitogen-induced lymphocyte proliferation, reducing the percentage of proliferating T and B cells. Notably, both CBD doses did not exhibit cytotoxicity on lymphocytes as revealed by viability assessment. We also analysed the effect of CBD on U937 cells using an optical microscopy approach. Interestingly, the higher dose of CBD exerted a cytotoxic effect on U937 cells, while the lower dose was well tolerated. Results: We analysed the effect of an adjuvant treatment for atopic dermatitis with a CBD-containing cleansing cream in reducing itch. Notably, the treatment with the CBD-containing cleansing cream significantly reduced itch in patients suffering from atopic dermatitis. Conclusions: These findings affirm CBD's immunomodulatory characteristics, emphasizing its potential therapeutic application in inflammatory skin disorders. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective study

Author

Bariletto, Giuseppe, Carbonara, Annamaria, Cataldo, Vito, Damiani, Elisabetta, Di Leo, Elisabetta, Fiorino, Irene, Kourtis, Georgios, Laudadio, Valentina, Loconte, Filomena, Lotti, Anita, Mastromarco, Enza, Nenna, Saverio, Nico, Andrea, Pietrafesa, Maria, Rucco, Anna Simona, Strada, Silvana, Di Bona, Danilo, Magistà, Stefania, Masciopinto, Lucia, Lovecchio, Antonella, Loiodice, Roberto, Bilancia, Massimo, Albanesi, Marcello, Caiaffa, Maria Filomena, Nettis, Eustachio, and Macchia, Luigi

Published
2020
Full Text
View/download PDF

8. Successful treatment of refractory heat urticaria with omalizumab.

Author

Di Girolamo, Attilio, Miniello, Andrea, Casella, Rossella, Albanesi, Marcello, and Nettis, Eustachio

Subjects
DETECTION limit, MAST cells, PHYSICIANS, CELL receptors, PATIENTS' attitudes, URTICARIA
Abstract

This article discusses the successful treatment of refractory heat urticaria (HU) with omalizumab, a medication typically used for chronic spontaneous urticaria (CSU). HU is a rare and difficult-to-treat form of chronic inducible urticaria that develops in response to heat exposure. The article presents two cases of patients with refractory HU who experienced significant improvement in symptoms after receiving omalizumab treatment. Omalizumab works by reducing mast cell activation and histamine release. The findings suggest that omalizumab could be a safe and effective treatment option for HU patients who do not respond to conventional therapies. [Extracted from the article]

Published
2024
Full Text
View/download PDF

13. Allergy to ceftazidime/avibactam: diagnosis and desensitization.

Author

Cristallo, Mattia, Chaoul, Nada, Albanesi, Marcello, Nettis, Eustachio, and Di Girolamo, Attilio

Subjects
CEFTAZIDIME, DESENSITIZATION (Psychotherapy), BETA lactam antibiotics
Abstract

This document is a letter to the editor discussing the diagnosis and desensitization of an allergy to the antibiotic ceftazidime/avibactam. The authors describe a case of a 63-year-old female who developed urticaria after receiving the antibiotic and underwent a rapid desensitization protocol to continue the treatment. They used a flow cytometry-based assay to investigate the specific components of the antibiotic that triggered the hypersensitivity reaction. The authors conclude that the desensitization protocol was safe and effective, allowing the patient to complete the antibiotic therapy without further adverse reactions. [Extracted from the article]

Published
2024
Full Text
View/download PDF

20. Sustained drug-related reaction with eosinophilia and systemic symptoms (DRESS) triggered by low molecular weight heparins in COVID-19: management and precision diagnosis

Author

Minenna, Elena, primary, Chaoul, Nada, additional, Pia Rossi, Maria, additional, Giliberti, Lucia, additional, Albanesi, Marcello, additional, Nettis, Eustachio, additional, Foschino Barbaro, Maria Pia, additional, Bona, Danilo Di, additional, Caiaffa, Maria Filomena, additional, and Macchia, Luigi, additional

Published
2022
Full Text
View/download PDF

22. Sustained Drug-related Reaction With Eosinophilia and Systemic Symptoms (DRESS) Triggered by Low Molecular Weight Heparins in COVID-19: Management and Precision Diagnosis.

Author

Minenna, Elena, primary, Chaoul, Nada, additional, Rossi, Maria Pia, additional, Giliberti, Lucia, additional, Albanesi, Marcello, additional, Nettis, Eustachio, additional, Barbaro, Maria Pia Foschino, additional, Bona, Danilo Di, additional, Caiaffa, Maria Filomena, additional, and Macchia, Luigi, additional

Published
2021
Full Text
View/download PDF

23. Application of average volume assured pressure support (AVAPS) and ultrasound assessment in COVID-19 infection: real-life observation

Author

CRUDELE, Lucilla, primary, ALBANESI, Marcello, additional, DE LUCA, Paola, additional, SOLLAZZO, Enza P., additional, PISTONE, Antonietta, additional, DELL’AQUILA, Paola, additional, DE MATTEIS, Sandra, additional, POZZESSERE, Pietro, additional, LOMAZZO, Daniela, additional, MELODIA, Rosa, additional, RACANELLI, Vito, additional, VACCA, Angelo, additional, and PROCACCI, Vito, additional

Published
2021
Full Text
View/download PDF

28. Desensitization in Iron Product Allergy

Author

Di Girolamo, Attilio, primary, Albanesi, Marcello, additional, Loconte, Filomena, additional, Di Bona, Danilo, additional, Caiaffa, Maria Filomena, additional, and Macchia, Luigi, additional

Published
2020
Full Text
View/download PDF

29. Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective study

Author

Di Bona, Danilo, primary, Magistà, Stefania, additional, Masciopinto, Lucia, additional, Lovecchio, Antonella, additional, Loiodice, Roberto, additional, Bilancia, Massimo, additional, Albanesi, Marcello, additional, Caiaffa, Maria Filomena, additional, Nettis, Eustachio, additional, Macchia, Luigi, additional, Bariletto, Giuseppe, additional, Carbonara, Annamaria, additional, Cataldo, Vito, additional, Damiani, Elisabetta, additional, Di Leo, Elisabetta, additional, Fiorino, Irene, additional, Kourtis, Georgios, additional, Laudadio, Valentina, additional, Loconte, Filomena, additional, Lotti, Anita, additional, Mastromarco, Enza, additional, Nenna, Saverio, additional, Nico, Andrea, additional, Pietrafesa, Maria, additional, Rucco, Anna Simona, additional, and Strada, Silvana, additional

Published
2020
Full Text
View/download PDF

30. Mast cells and cancer

Author

Paolino, Giovanni, primary, Corsetti, Paola, additional, Moliterni, Elisa, additional, Corsetti, Serena, additional, Didona, Dario, additional, Albanesi, Marcello, additional, Mattozzi, Carlo, additional, Lido, Paolo, additional, and Calvieri, Stefano, additional

Published
2019
Full Text
View/download PDF

31. MOESM1 of A 13-year real-life study on efficacy, safety and biological effects of Vespula venom immunotherapy

Author

Albanesi, Marcello, Nico, Andrea, Sinisi, Alessandro, Giliberti, Lucia, Rossi, Maria, Rossini, Margherita, Kourtis, Georgios, Rucco, Anna, Loconte, Filomena, Muolo, Loredana, Zurlo, Marco, Bona, Danilo, Caiaffa, Maria, and Macchia, Luigi

Abstract

Additional file 1: Table S1. Comparative table of the existing reports on long-term clinical efficacy of VIT.

Published
2018
Full Text
View/download PDF

36. A 13-year real-life study on efficacy, safety and biological effects of Vespula venom immunotherapy

Author

Albanesi, Marcello, primary, Nico, Andrea, additional, Sinisi, Alessandro, additional, Giliberti, Lucia, additional, Rossi, Maria Pia, additional, Rossini, Margherita, additional, Kourtis, Georgios, additional, Rucco, Anna Simona, additional, Loconte, Filomena, additional, Muolo, Loredana, additional, Zurlo, Marco, additional, Di Bona, Danilo, additional, Caiaffa, Maria Filomena, additional, and Macchia, Luigi, additional

Published
2018
Full Text
View/download PDF

39. Delayed allergy to acyclovir revealed by lymphocyte proliferation test

Author

Albanesi, Marcello, primary, Di Girolamo, Attilio, additional, Aresta, Vincenzo, additional, Rossi, Maria Pia, additional, Giliberti, Lucia, additional, Perrone, Tommasina, additional, Bona, Danilo Di, additional, Caiaffa, Maria Filomena, additional, Specchia, Giorgina, additional, and Macchia, Luigi, additional

Published
2018
Full Text
View/download PDF

44. Récepteurs, cellules et mécanismes impliqués dans la thérapie anti-tumorale à base d'anticorps monoclonaux

Author

Albanesi, Marcello, Allergologie Moléculaire et Cellulaire, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris VI, Pierre Bruhns, and Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
mélanome, anticorps thérapeutiques, récepteurs Fc, cancer du sein, cancer, [SDV.IMM]Life Sciences [q-bio]/Immunology, neoplasms, neutrophiles
Abstract

Monoclonal antibodies (mAbs) can be used to specifically target tumor cells over-expressing specific antigens. In most of the cases, the binding of the mAbs on the target antigen enables via the Fc portion of mAbs the recruitment of phagocytic and/or cytotoxic immune cells bearing receptors for the Fc portion of IgG (FcγR). Several FcγRs exist that differ from each other for both their functional activity and expression pattern among immune cells. Moreover, numerous differences exist between mouse and human FcγRs. However, which of the different FcγRs and which cell population is required for in vivo tumor regression following mAb therapy is not known. During my PhD, I have set up two mouse models of cancer mAb therapy: a syngenic (B16 melanoma) and a xenogenic model (BT474 human breast cancer). In the B16 melanoma model, an intravenous injection of B16 melanoma cells in wt mice leads to the development of lung metastases, whereas a subcutaneous injection leads to a solid tumor. A treatment with the mAb TA99 that targets the glycoprotein gp75 expressed on the B16 cells, results in a reduction of the tumor load. Likewise, the subcutaneous engraftment of BT474 human breast cancer cells in immunodeficient mice leads to a development of a solid tumor. Recurrent injections of the humanized mAb Trastuzumab, that targets the HER2 antigen expressed on the BT474 cells, leads to a reduction of the tumor load. Using these models I have identified the mouse (FcγRI and FcγRIII) and human (hFcyRI and hFcyRIIA) FcyRs involved in mAb anti-tumor activity. Moreover I have identified neutrophils as cell population responsible for the anti-tumor effect of therapeutic mAbs.; Les antigènes exprimés sur les cellules cancéreuses peuvent être ciblées par des anticorps monoclonaux thérapeutiques (mAbs) capables, d'induire une réduction de la masse tumorale. Dans la plupart des cas, la fixation des mAbs à la surface des cellules tumorales induit, par la portion Fc, le recrutement de cellules phagocytaires et cytotoxiques qui expriment des récepteurs pour la pour la portion Fc des IgG (RFcy). Chez l'homme et chez la souris plusieurs RFcy existent et ont différentes fonctions et expression à la surface des cellules hématopoïétiques. En revanche, lequel parmi les multiples RFcy est responsable pour l'activité thérapeutique des anticorps monoclonaux n'est pas connu, ni quelle population cellulaire qui les exprime est responsable de la destruction des cellules tumorales. Au cours de ma thèse j'ai développé deux modèles d'immunothérapie à base d'anticorps monoclonaux chez la souris : un modèle syngenique (Melanome B16) et un modèle xenogenique (Cancer du sein humain BT474). Dans ces modèles, l'injection de l'anticorps murin TA99 qui reconnaît la protéine gp75 exprimée par les cellules tumorales B16, d'une part, et l'injection de l'anticorps humanisé Trastuzumab qui reconnaît le récepteur HER2 exprimé par les cellules BT474, d'autre part, induit une réduction de la masse tumorale. En utilisant ces deux modèles j'ai identifié des récepteurs murins (RFcyI/RFcyIII) et humains (RFcyI/RFcyIIA) responsables de l'activité anti tumorale de ces anticorps. De plus, j'ai identifié les neutrophiles comme population cellulaire responsable de la destruction des cellules tumorales en présence des anticorps thérapeutiques.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results